Five companies control a quarter of Africa's trial landscape.
Top 5 Pharma Share
22%
Local Industry
Minimal
Foreign Sponsors
65%+
Dependency Index
High
Key Finding
The five largest global pharmaceutical companies sponsored an estimated twenty-two percent of African trials, while foreign sponsors collectively accounted for over sixty-five percent of all registrations.
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Placebo: AF 3,324 vs US 33,931 (10.2x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
The top five global pharmaceutical companies control 22% of Africa's clinical trial landscape, and foreign sponsors overall account for over 65% of all African trials. With virtually no local pharmaceutical industry, Africa has no counterweight to corporate research agendas. Trial priorities are set in boardrooms in New York, Basel, and London — not in the hospitals of Kampala, Nairobi, or Lagos.
The Evidence 144 words · target 156
In research economics, does the concentration of pharmaceutical sponsorship indicate corporate capture of Africa's clinical trial landscape? This audit evaluated lead sponsor identity for 23,873 African interventional trials using ClinicalTrials.gov sponsor metadata through March 2026. Investigators reported the top-five sponsor concentration ratio as the primary estimand for corporate influence. The five largest global pharmaceutical companies sponsored an estimated twenty-two percent of African trials, while foreign sponsors collectively accounted for over sixty-five percent of all registrations. Local African pharmaceutical industry sponsored fewer than three percent of trials, creating a total dependency on foreign corporate agendas for clinical innovation priorities. Placebo-controlled trials numbered 3,324 in Africa (14% of total) versus 33,931 in the United States (18%). These findings demonstrate that Africa's research agenda is set in corporate boardrooms rather than African public health institutions. Interpretation is limited by the classification of academic-industry partnerships as single-sponsor entries.
Sentence Structure
Question
In research economics, does the concentration of pharmaceutical sponsorship indicate corporate capture of Africa's clinical trial landscape?
Dataset
This audit evaluated lead sponsor identity for 23,873 African interventional trials using ClinicalTrials.gov sponsor metadata through March 2026.
Method
Investigators reported the top-five sponsor concentration ratio as the primary estimand for corporate influence.
Primary Result
The five largest global pharmaceutical companies sponsored an estimated twenty-two percent of African trials, while foreign sponsors collectively accounted for over sixty-five percent of all registrations.
Robustness
Local African pharmaceutical industry sponsored fewer than three percent of trials, creating a total dependency on foreign corporate agendas for clinical innovation priorities.
Interpretation
Placebo-controlled trials numbered 3,324 in Africa (14% of total) versus 33,931 in the United States (18%).
Boundary
These findings demonstrate that Africa's research agenda is set in corporate boardrooms rather than African public health institutions.